Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/222105
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pasnoor, Mamatha | - |
dc.contributor.author | Anderson Smits, Colin | - |
dc.contributor.author | Levine, Todd | - |
dc.contributor.author | Bril, Vera | - |
dc.contributor.author | Marcos Solano, Juan | - |
dc.contributor.author | Rejdak, Konrad | - |
dc.contributor.author | Gamez, Josep | - |
dc.contributor.author | Chroni, Elisabeth | - |
dc.contributor.author | Casasnovas, Carlos | - |
dc.contributor.author | Marchioni, Enrico | - |
dc.contributor.author | Siciliano, Gabriele | - |
dc.contributor.author | Cocito, Dario | - |
dc.contributor.author | Sivakumar, K. | - |
dc.contributor.author | Rivero, Alberto | - |
dc.contributor.author | Duff, Kim | - |
dc.contributor.author | Greco, Erin | - |
dc.contributor.author | Corbo, Massimo | - |
dc.contributor.author | Hasan, Shabbir | - |
dc.contributor.author | Dori, Amir | - |
dc.contributor.author | Schmidt, Jens | - |
dc.contributor.author | Wood, Jamie | - |
dc.contributor.author | Li, Zhaoyang | - |
dc.contributor.author | Ay, Hakan | - |
dc.date.accessioned | 2025-07-08T10:44:16Z | - |
dc.date.available | 2025-07-08T10:44:16Z | - |
dc.date.issued | 2025-04-01 | - |
dc.identifier.issn | 1468-1331 | - |
dc.identifier.uri | https://hdl.handle.net/2445/222105 | - |
dc.description.abstract | Background ADVANCE-CIDP IVIG evaluated the efficacy and safety of immune globulin infusion (human) 10% solution (IVIG 10%; GAMMAGARD LIQUID, also known as Kiovig) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) as a rescue treatment for patients relapsing during the ADVANCE-CIDP 1 trial.MethodsOpen-label ADVANCE-CIDP IVIG included adult patients with confirmed CIDP relapse (>= 1-point increase in adjusted Inflammatory Neuropathy Cause and Treatment [INCAT] disability scores from pre-treatment baseline) during ADVANCE-CIDP 1, which assessed the efficacy and safety of hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10%. Patients received an induction IVIG 10% dose (2 g/kg) followed by maintenance infusions at the same monthly equivalent dose of pre-randomization IVIG, 3-weekly for 6 months. The primary outcome was the responder rate (>= 1-point decrease in adjusted INCAT scores at treatment cessation vs. pre-IVIG 10% baseline, in patients receiving placebo in ADVANCE-CIDP 1). Other outcomes included the responder rate across all patients relapsing on fSCIG 10% or placebo in ADVANCE-CIDP 1, time to functional improvement (>= 1-point decrease in adjusted INCAT score), and change in adjusted INCAT scores and Rasch-built Overall Disability Scale (R-ODS) centile scores from pre-IVIG 10% baseline.ResultsOverall, 20 patients received IVIG 10% (n = 4 [fSCIG 10%-relapse group]; n = 16 [placebo-relapse group]). Responder rate (95% confidence interval) was 100.0% (80.6%-100.0%) in the placebo-relapse group and 95.0% (76.4%-99.1%) in the overall-relapse population. Across all patients, median time to functional improvement was 25 days. At treatment cessation, mean changes from pre-IVIG 10% baseline in adjusted INCAT and R-ODS centile scores were -1.9 and 12.9, respectively.ConclusionsIVIG 10% effectively treated CIDP relapse and improved functional abilities. | - |
dc.format.extent | 11 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Wiley | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1111/ene.70110 | - |
dc.relation.ispartof | European Journal of Neurology, 2025, vol. 32, num. 4, p. e70110 | - |
dc.relation.uri | https://doi.org/10.1111/ene.70110 | - |
dc.rights | cc by-nc (c) Pasnoor, Mamatha et al., 2025 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Malalties autoimmunitàries | - |
dc.subject.classification | Immunoglobulina G | - |
dc.subject.classification | Immunoglobulines | - |
dc.subject.classification | Malalties del sistema nerviós | - |
dc.subject.other | Autoimmune diseases | - |
dc.subject.other | Immunoglobulin G | - |
dc.subject.other | Immunoglobulins | - |
dc.subject.other | Nervous system Diseases | - |
dc.title | The Results of ADVANCE-CIDP IVIG Trial: Intravenous Immunoglobulin 10% Therapy With GAMMAGARD LIQUID Kiovig for Treatment of Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2025-06-19T14:41:00Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 40247653 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Euro J of Neurology - 2025 - Pasnoor - The Results of ADVANCE‐CIDP IVIG Trial Intravenous Immunoglobulin 10 Therapy With.pdf | 825.27 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License